Search
Results: 138
Screening for Barrett's Esophagus
New improved methods are required for the early detection of esophageal adenocarcinoma in order to reduce mortality from this aggressive cancer. In this review we discuss different screening methods which are currently under...
Circulating tumor DNA in patients with colorectal adenomas
Ni Ni Moe Myint, Ajay M Verma, Daniel Fernandez-Garcia, Panchali Sarmah, Patrick S Tarpey, Saif Sattar Al-Aqbi, Hong Cai, Ricky Trigg, Kevin West, Lynne M Howells, Anne Thomas, Karen Brown, David S Guttery, Baljit Singh, Howard J Pringle, Ultan McDermott, Jacqui A Shaw, Alessandro Rufini
Nov 22, 2018
Improving early detection of colorectal cancer (CRC) is a key public health priority as adenomas and stage I cancer can be treated with minimally invasive procedures. Population screening strategies based on detection of occult...
Adenoma Adenomatous Polyposis Coli Protein Aged Aged 80 and over Animals Biomarkers Tumor Circulating Tumor DNA Colonic Neoplasms Early Detection of Cancer Female High-Throughput Nucleotide Sequencing Humans Liquid biopsy Male Mice Mice Knockout Middle Aged Polymerase Chain Reaction Proto-Oncogene Proteins B-raf Proto-Oncogene Proteins p21(ras)
The Costs and Benefits of Risk Stratification for Colorectal Cancer Screening Based On Phenotypic and Genetic Risk
Chloe Thomas, Olena Mandrik, Catherine L Saunders, Deborah Thompson, Sophie Whyte, Simon Griffin, Juliet A Usher-Smith
May 28, 2021
Population-based screening for colorectal cancer is an effective and cost-effective way of reducing colorectal cancer incidence and mortality. Many genetic and phenotypic risk factors for colorectal cancer have been identified...
Adult Aged Aged 80 and over Colonoscopy Colorectal Neoplasms Cost-Benefit Analysis Early Detection of Cancer England Female Genetic Predisposition to Disease Genetic Testing Humans Incidence Life Style Male Mass Screening Middle Aged Models Statistical Occult Blood Phenotype Risk Assessment Risk Factors State Medicine
Experiences of 'traditional' and 'one-stop' MRI-based prostate cancer diagnostic pathways in England
Samuel William David Merriel, Stephanie Archer, Alice S Forster, David Eldred-Evans, John McGrath, Hashim Uddin Ahmed, Willie Hamilton, Fiona M Walter
Sep 02, 2022
Magnetic Resonance Imaging PRIMARY CARE prostate disease qualitative research urological tumours Adult Aged Aged 80 and over Attitude of Health Personnel Early Detection of Cancer England general practitioners Humans Magnetic Resonance Imaging Male Middle Aged Prostate-specific antigen Prostatic Neoplasms qualitative research State Medicine
Cervical cell lift
Aslam Shiraz, Nagayasu Egawa, Daniël M Pelt, Robin Crawford, Adeline K Nicholas, Veronika Romashova, Peter Sasieni, Heather Griffin, John Doorbar
Aug 21, 2022
BACKGROUND: Primary HPV screening, due to its low specificity, requires an additional liquid-based cytology (LBC) triage test. However, even with LBC triage there has been a near doubling in the number of patients referred for...
Biomarker for cervical screening CIN Cervical cancer Cytology HPV Methodology for cervical screening Non-invasive sampling Spatial mapping of lesion Triage test Cervix Uteri Early Detection of Cancer Female Humans Papillomaviridae Papillomavirus Infections Pilot Projects Precancerous Conditions Triage Uterine Cervical Neoplasms Vaginal Smears Uterine Cervical Dysplasia
Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models
Renée T Fortner, Allison F Vitonis, Helena Schock, Anika Hüsing, Theron Johnson, Raina N Fichorova, Titilayo Fashemi, Hidemi S Yamamoto, Anne Tjønneland, Louise Hansen, Kim Overvad, Marie-Christine Boutron-Ruault, Marina Kvaskoff, Gianluca Severi, Heiner Boeing, Antonia Trichopoulou, Vassiliki Benetou, Carlo La Vecchia, Domenico Palli, Sabina Sieri, Rosario Tumino, Giuseppe Matullo, Amalia Mattiello, N Charlotte Onland-Moret, Petra H Peeters, Elisabete Weiderpass, Inger Torhild Gram, Mie Jareid, J Ramón Quirós, Eric J Duell, Maria-Jose Sánchez, María Dolores Chirlaque, Eva Ardanaz, Nerea Larrañaga, Björn Nodin, Jenny Brändstedt, Annika Idahl, Kay-Tee Khaw, Naomi Allen, Marc Gunter, Mattias Johansson, Laure Dossus, Melissa A Merritt, Elio Riboli, Daniel W Cramer, Rudolf Kaaks, Kathryn L Terry
May 05, 2017
BACKGROUND: Ovarian cancer early detection markers CA125, CA15.3, HE4, and CA72.4 vary between healthy women, limiting their utility for screening. METHODS: We evaluated cross-sectional relationships between lifestyle and...
Risk profiles of prostate cancers identified from UK primary care using national referral guidelines
H Serag, S Banerjee, K Saeb-Parsy, S Irving, K Wright, S Stearn, A Doble, VJ Gnanapragasam
Mar 31, 2017
OBJECTIVE: Prostate cancer in the United Kingdom is mainly diagnosed from primary care referrals based on national guidelines published by the Department of Health. Here we investigated the characteristics of cancers detected...
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score.
Minh-Phuong Huynh-Le, Roshan Karunamuni, Chun Chieh Fan, Lui Asona, Wesley K Thompson, Maria Elena Martinez, Rosalind A Eeles, Zsofia Kote-Jarai, Kenneth R Muir, Artitaya Lophatananon, Johanna Schleutker, Nora Pashayan, Jyotsna Batra, Henrik Grönberg, David E Neal, Børge G Nordestgaard, Catherine M Tangen, Robert J Macinnis, Alicja Wolk, Demetrius Albanes, Christopher A Haiman, Ruth C Travis, William J Blot, Janet L Stanford, Lorelei A Mucci, Catharine ML West, Sune F Nielsen, Adam S Kibel, Olivier Cussenot, Sonja I Berndt, Stella Koutros, Karina Dalsgaard Sørensen, Cezary Cybulski, Eli Marie Grindedal, Florence Menegaux, Jong Y Park, Sue A Ingles, Christiane Maier, Robert J Hamilton, Barry S Rosenstein, Yong-Jie Lu, Stephen Watya, Ana Vega, Manolis Kogevinas, Fredrik Wiklund, Kathryn L Penney, Chad D Huff, Manuel R Teixeira, Luc Multigner, Robin J Leach, Hermann Brenner, Esther M John, Radka Kaneva, Christopher J Logothetis, Susan L Neuhausen, Kim De Ruyck, Piet Ost, Azad Razack, Lisa F Newcomb, Jay H Fowke, Marija Gamulin, Aswin Abraham, Frank Claessens, Jose Esteban Castelao, Paul A Townsend, Dana C Crawford, Gyorgy Petrovics, Ron HN van Schaik, Marie-Élise Parent, Jennifer J Hu, Wei Zheng, UKGPCS collaborators, APCB (Australian Prostate Cancer BioResource), NC-LA PCaP Investigators, IMPACT Study Steering Committee and Collaborators, Canary PASS Investigators, Profile Study Steering Committee, PRACTICAL Consortium, Ian G Mills, Ole A Andreassen, Anders M Dale, Tyler M Seibert
Jan 12, 2023
Circulating Osteopontin and Prediction of Hepatocellular Carcinoma Development in a Large European Population.
Talita Duarte-Salles, Sandeep Misra, Magdalena Stepien, Amelie Plymoth, David Muller, Kim Overvad, Anja Olsen, Anne Tjønneland, Laura Baglietto, Gianluca Severi, Marie-Christine Boutron-Ruault, Renee Turzanski-Fortner, Rudolf Kaaks, Heiner Boeing, Krasimira Aleksandrova, Antonia Trichopoulou, Pagona Lagiou, Christina Bamia, Valeria Pala, Domenico Palli, Amalia Mattiello, Rosario Tumino, Alessio Naccarati, HB As Bueno-de-Mesquita, Petra H Peeters, Elisabete Weiderpass, J Ramón Quirós, Antonio Agudo, Emilio Sánchez-Cantalejo, Eva Ardanaz, Diana Gavrila, Miren Dorronsoro, Mårten Werner, Oskar Hemmingsson, Bodil Ohlsson, Klas Sjöberg, Nicholas J Wareham, Kay-Tee Khaw, Kathryn E Bradbury, Marc J Gunter, Amanda J Cross, Elio Riboli, Mazda Jenab, Pierre Hainaut, Laura Beretta
Jul 27, 2016
Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening.
Valerie Jenkins, Lesley Fallowfield, Carolyn Langridge, Jessica Barrett, Andy Ryan, Ian Jacobs, Justine Kilkerr, Usha Menon, Vernon Farewell
Jun 17, 2015
A comparative study of endoscopic surveillance in hereditary diffuse gastric cancer according to CDH1 mutation status
R Fitzgerald, M Tischkowitz, M di Pietro, M O'Donovan, S Richardson, EM Mi, E Mi, R Hardwick, H Ziauddeen, PC Fletcher, C Caldas, K Ragunath
Jul 20, 2017
Background and aims Hereditary Diffuse Gastric Cancer (HDGC) accounts for 1% of gastric cancer cases. For patients with a germline CDH1 mutation, risk-reducing gastrectomy is recommended. However, for those delaying surgery or...
Identification of pathologically insignificant prostate cancer is not accurate in unscreened men.
GL Shaw, BC Thomas, SN Dawson, G Srivastava, SL Vowler, VJ Gnanapragasam, NC Shah, AY Warren, DE Neal
Jun 11, 2018
BACKGROUND: Identification of men harbouring insignificant prostate cancer (PC) is important in selecting patients for active surveillance. Tools have been developed in PSA-screened populations to identify such men based on...
Adenocarcinoma Aged Area Under Curve Biopsy Needle Early Detection of Cancer False Negative Reactions Humans Lymphatic Metastasis Magnetic Resonance Imaging Male Middle Aged Neoplasm Grading Neoplasm Staging Organ Size Patient Selection Predictive Value of Tests Prostate Prostate-specific antigen Prostatic Neoplasms ROC Curve Retrospective Studies Risk Assessment Seminal vesicles Sensitivity and Specificity Tumor Burden Watchful Waiting
Diagnosing cancer in primary care
Ruth Swann, Sean McPhail, Jana Witt, Brian Shand, Gary A Abel, Sara Hiom, Jem Rashbass, Georgios Lyratzopoulos, Greg Rubin, National Cancer Diagnosis Audit Steering Group
Mar 07, 2018
BACKGROUND: Continual improvements in diagnostic processes are needed to minimise the proportion of patients with cancer who experience diagnostic delays. Clinical audit is a means of achieving this. AIM: To characterise key...
The use of a risk assessment and decision support tool (CRISP) compared with usual care in general practice to increase risk-stratified colorectal cancer screening
Jennifer G Walker, Finlay Macrae, Ingrid Winship, Jasmeen Oberoi, Sibel Saya, Shakira Milton, Adrian Bickerstaffe, James G Dowty, Richard De Abreu Lourenço, Malcolm Clark, Louise Galloway, George Fishman, Fiona M Walter, Louisa Flander, Patty Chondros, Driss Ait Ouakrim, Marie Pirotta, Lyndal Trevena, Mark A Jenkins, Jon D Emery
Sep 05, 2018
BACKGROUND: Australia and New Zealand have the highest incidence rates of colorectal cancer worldwide. In Australia there is significant unwarranted variation in colorectal cancer screening due to low uptake of the...
colorectal cancer screening Decision support Faecal occult blood test General Practice Precision Medicine Precision screening PRIMARY CARE Risk assessment tool risk-stratified screening Aged Clinical Trials Phase II as Topic Colorectal Neoplasms Decision Support Techniques Early Detection of Cancer Female General Practice Humans Male Middle Aged Multicenter Studies as Topic Predictive Value of Tests Primary Health Care Prognosis Randomized Controlled Trials as Topic Risk Assessment Risk Factors Time Factors Victoria
A Decision Analysis Evaluating Screening for Kidney Cancer Using Focused Renal Ultrasound.
Sabrina H Rossi, Tobias Klatte, Juliet A Usher-Smith, Kate Fife, Sarah J Welsh, Saeed Dabestani, Axel Bex, David Nicol, Paul Nathan, Grant D Stewart, Edward Cf Wilson
Sep 13, 2019
Faecal immunochemical test to triage patients with abdominal symptoms for suspected colorectal cancer in primary care
Marije van Melle, Samir IS Yep Manzano, Hugh Wilson, Willie Hamilton, Fiona M Walter, Sarah ER Bailey
Apr 20, 2020
BACKGROUND: Recently, faecal immunochemical tests (FITs) have been introduced for investigation of primary care patients with low-risk symptoms of colorectal cancer (CRC), but recommendations vary across the world. This...
Acceptability and potential impact on uptake of using different risk stratification approaches to determine eligibility for screening
Juliet A Usher-Smith, Laragh LW Harvey-Kelly, Sabrina H Rossi, Hannah Harrison, Simon J Griffin, Grant D Stewart
Nov 17, 2020
A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer
Silvana Debernardi, Harrison O'Brien, Asma S Algahmdi, Nuria Malats, Grant D Stewart, Marija Plješa-Ercegovac, Eithne Costello, William Greenhalf, Amina Saad, Rhiannon Roberts, Alexander Ney, Stephen P Pereira, Hemant M Kocher, Stephen Duffy, Oleg Blyuss, Tatjana Crnogorac-Jurcevic
Nov 23, 2020
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers, with around 9% of patients surviving >5 years. Asymptomatic in its initial stages, PDAC is mostly diagnosed late, when already a locally...
Adult Aged Aged 80 and over Antigens Tumor-Associated Carbohydrate Biomarkers Tumor Carcinoma Pancreatic Ductal Early Detection of Cancer Europe Female Humans Lithostathine Male Middle Aged Pancreatic Neoplasms Predictive Value of Tests Reproducibility of Results Retrospective Studies Trefoil Factor-1 Urinalysis Vesicular Transport Proteins Young Adult
A genetic risk score to personalize prostate cancer screening, applied to population data.
Minh-Phuong Huynh-Le, Chun Chieh Fan, Roshan Karunamuni, Eleanor I Walsh, Emma L Turner, J Athene Lane, Richard M Martin, David E Neal, Jenny L Donovan, Freddie C Hamdy, J Kellogg Parsons, Rosalind A Eeles, Douglas F Easton, Zsofia Kote-Jarai, Ali Amin Al Olama, Sara Benlloch Garcia, Kenneth Muir, Henrik Gronberg, Fredrik Wiklund, Markus Aly, Johanna Schleutker, Csilla Sipeky, Teuvo LJ Tammela, Børge G Nordestgaard, Timothy J Key, Ruth C Travis, Paul DP Pharoah, Nora Pashayan, Kay-Tee Khaw, Stephen N Thibodeau, Shannon K McDonnell, Daniel J Schaid, Christiane Maier, Walther Vogel, Manuel Luedeke, Kathleen Herkommer, Adam S Kibel, Cezary Cybulski, Dominika Wokolorczyk, Wojciech Kluzniak, Lisa A Cannon-Albright, Hermann Brenner, Ben Schöttker, Bernd Holleczek, Jong Y Park, Thomas A Sellers, Hui-Yi Lin, Chavdar Kroumov Slavov, Radka P Kaneva, Vanio I Mitev, Jyotsna Batra, Judith A Clements, Amanda B Spurdle, Manuel R Teixeira, Paula Paulo, Sofia Maia, Hardev Pandha, Agnieszka Michael, Ian G Mills, Ole A Andreassen, Anders M Dale, Tyler M Seibert
Jul 03, 2020
Background: A polygenic hazard score (PHS)—the weighted sum of 54 SNP genotypes—was previously validated for association with clinically significant prostate cancer and for improved prostate cancer screening accuracy. Here, we...
The incidence of cervical cancer in women with postcoital bleeding and abnormal appearance of the cervix referred through the 2-week wait pathway in the United Kingdom
AIM: To determine the incidence of cervical cancer in women referred through the 2-week-wait pathway for postcoital bleeding and abnormal appearance of the cervix. METHODS: A retrospective cohort study was conducted of women...
cervical intraepithelial neoplasia colposcopy Incidence Referral and Consultation Uterine Cervical Neoplasms Pregnancy Female Humans Uterine Cervical Neoplasms Cervix Uteri Colposcopy Early Detection of Cancer Incidence Retrospective Studies Referral and Consultation Hemorrhage United Kingdom Uterine Cervical Dysplasia
Cell-free DNA technologies for the analysis of brain cancer.
Survival for glioma patients has shown minimal improvement over the past 20 years. The ability to detect and monitor gliomas relies primarily upon imaging technologies that lack sensitivity and specificity, especially during the...
UroMark-a urinary biomarker assay for the detection of bladder cancer.
Andrew Feber, Pawan Dhami, Liqin Dong, Patricia de Winter, Wei Shen Tan, Mónica Martínez-Fernández, Dirk S Paul, Antony Hynes-Allen, Sheida Rezaee, Pratik Gurung, Simon Rodney, Ahmed Mehmood, Felipe Villacampa, Federico de la Rosa, Charles Jameson, Kar Keung Cheng, Maurice P Zeegers, Richard T Bryan, Nicholas D James, Jesus M Paramio, Alex Freeman, Stephan Beck, John D Kelly
Mar 26, 2018
BACKGROUND: Bladder cancer (BC) is one of the most common cancers in the western world and ranks as the most expensive to manage, due to the need for cystoscopic examination. BC shows frequent changes in DNA methylation, and...
bladder cancer Diagnostic epigenetics Next generation sequencing Urine Adult Aged Aged 80 and over Biomarkers Tumor CpG Islands DNA Methylation DNA Neoplasm Early Detection of Cancer Epigenesis Genetic Female High-Throughput Nucleotide Sequencing Humans Male Middle Aged Sequence Analysis DNA Urinary Bladder Neoplasms Young Adult
|
|< |
< |
1 |